13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
56 檔
16.2%
According to the latest 13F quarterly dataset, Deep Track Capital, LP managed an equity portfolio of $6.9B at the end of Q3 2025, spanning 56 distinct U.S. exchange-listed positions.
In Q3 2025, Deep Track Capital, LP adopted a defensive or profit-taking posture, trimming 16 positions and completely liquidating 29 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GH | Guardant Health Inc | Stock-Healthcare | 7.24% | +2.37% | -2.26% | |
| 2 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 6.95% | +0.15% | -22.15% | |
| 3 | CYTK | Cytokinetics Inc | Stock-Healthcare | 6.60% | -0.61% | +17.81% | |
| 4 | AKRO | Akero Therapeutics Inc | Stock-Other | 5.30% | — | +31.50% | |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 5.05% | -2.98% | EXIT | |
| 6 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.98% | -0.76% | +71.43% | |
| 7 | IMVT | Immunovant Inc | Stock-Other | 4.38% | +0.56% | +2.41% | |
| 8 | DVAX | Dynavax Technologies CORP | Stock-Other | 4.36% | — | -11.61% | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.89% | +0.09% | -16.53% | |
| 10 | ETNBGBP | 89bio Inc | Stock-Other | 3.84% | — | -1.51% | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.29% | +0.33% | -17.88% | |
| 12 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.24% | +0.51% | — | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.18% | — | -47.14% | |
| 14 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.05% | -0.55% | +12.31% | |
| 15 | PCVX | Vaxcyte Inc | Stock-Other | 3.02% | -0.44% | +39.53% | |
| 16 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.86% | -0.08% | — | |
| 17 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 1.82% | -0.81% | — | |
| 18 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.74% | -1.02% | EXIT | |
| 19 | GERN | Geron CORP | Stock-Other | 1.57% | -0.77% | EXIT | |
| 20 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.57% | -0.92% | EXIT | |
| 21 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.56% | +1.12% | -0.13% | |
| 22 | MBX | Mbx Biosciences Inc | Stock-Other | 1.54% | +0.05% | +43.93% | |
| 23 | EXK | Exact Sciences CORP | Stock-Materials | 1.53% | — | — | |
| 24 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.48% | +0.23% | — | |
| 25 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.44% | +0.92% | — | |
| 26 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.42% | +1.04% | +38.36% | |
| 27 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.34% | — | -11.11% | |
| 28 | CMPS | Compass Pathways PLC | Stock-Other | 1.26% | +1.40% | -11.00% | |
| 29 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.15% | -0.75% | EXIT | |
| 30 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.07% | +0.45% | — | |
| 31 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.95% | +0.27% | NEW | |
| 32 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.80% | — | +20.00% | |
| 33 | QURE | uniQure N.V. | Stock-Other | 0.79% | — | — | |
| 34 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.71% | -0.11% | — | |
| 35 | JBIO | Jade Biosciences Inc | Stock-Other | 0.55% | — | -9.14% | |
| 36 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.54% | — | — | |
| 37 | GHRS | GH Research PLC | Stock-Other | 0.50% | +1.30% | NEW | |
| 38 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.49% | — | -40.00% | |
| 39 | ✓ | Engene Holdings Inc | Stock-Other | 0.43% | -0.49% | EXIT | |
| 40 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.41% | +1.86% | — | |
| 41 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.34% | +0.97% | — | |
| 42 | CNTX | Context Therapeutics Inc | Stock-Other | 0.20% | -0.26% | — | |
| 43 | IMA | Imagenebio Inc | Stock-Other | 0.20% | — | — | |
| 44 | XNCR | Xencor Inc | Stock-Other | 0.18% | +0.14% | NEW | |
| 45 | HELP | Cybin Inc | Stock-Other | 0.16% | -0.10% | EXIT | |
| 46 | CRMD | Cormedix Inc | Stock-Other | 0.16% | +0.02% | — | |
| 47 | PEPG | Pepgen Inc | Stock-Other | 0.15% | — | — | |
| 48 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.15% | -0.14% | EXIT | |
| 49 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.12% | -0.01% | — | |
| 50 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.12% | — | -84.76% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CYTK | Cytokinetics Inc | +2.6% | +17.81% | Add |
| 2 | TARS | Tarsus Pharmaceuticals Inc | +2.5% | +71.43% | Add |
| 3 | IONS | Ionis Pharmaceuticals Inc | +2.5% | -22.15% | Trim |
| 4 | PCVX | Vaxcyte Inc | +2.1% | +39.53% | Add |
| 5 | MAZE | Maze Therapeutics Inc | +1.7% | — | Add |
| 6 | ETNBGBP | 89bio Inc | +1.7% | -1.51% | Add |
| 7 | APLSUSD | Apellis Pharmaceuticals Inc | +1.5% | +14.29% | Add |
| 8 | AKRO | Akero Therapeutics Inc | +1.1% | +31.50% | Add |
| 9 | 430 | Terns Pharmaceuticals Inc | +1.1% | — | Add |
| 10 | GPCR | Structure Therapeutics Inc | +1% | -17.88% | Add |
| 11 | ORKA | Oruka Therapeutics Inc | +0.9% | +38.36% | Add |
| 12 | VRDN | Viridian Therapeutics Inc | +0.9% | — | Unchanged |
| 13 | MBX | Mbx Biosciences Inc | +0.8% | +43.93% | Add |
| 14 | OLMA | Olema Pharmaceuticals Inc | +0.5% | +0.79% | Add |
| 15 | OCUL | Ocular Therapeutix Inc | +0.5% | -16.53% | Trim |
| 16 | IMCR | Immunocore Holdings Plc-adr | +0.5% | — | Add |
| 17 | CMPS | Compass Pathways PLC | +0.4% | -11.00% | Trim |
| 18 | CLDX | Celldex Therapeutics Inc | +0.3% | — | Unchanged |
| 19 | XENE | Xenon Pharmaceuticals Inc | +0.3% | -11.11% | Add |
| 20 | BCAX | Bicara Therapeutics Inc | +0.2% | — | Add |
| 21 | CNTX | Context Therapeutics Inc | +0.1% | — | Unchanged |
| 22 | DYN | Dyne Therapeutics Inc | 0% | — | Unchanged |
| 23 | BRD1EUR | Mind Medicine Mindmed Inc | 0% | -40.00% | Trim |
| 24 | ALGS | Aligos Therapeutics Inc | — | — | Unchanged |
| 25 | XNCR | Xencor Inc | 0% | — | Unchanged |
| 26 | CLYM | Climb Bio Inc | 0% | -50.99% | Trim |
| 27 | ✓ | Zura Bio LTD | -0.1% | -85.01% | Trim |
| 28 | HELP | Cybin Inc | -0.2% | -34.64% | Trim |
| 29 | AVTX | Avalo Therapeutics Inc | -0.2% | -74.50% | Trim |
| 30 | GHRS | GH Research PLC | -0.2% | -37.50% | Trim |
| 31 | ✓ | Engene Holdings Inc | -0.2% | -50.87% | Trim |
| 32 | GH | Guardant Health Inc | -0.3% | -2.26% | Trim |
| 33 | ANIP | Ani Pharmaceuticals Inc | -0.4% | -35.71% | Trim |
| 34 | GERN | Geron CORP | -0.4% | -4.43% | Add |
| 35 | NRIX | Nurix Therapeutics Inc | -0.6% | -0.13% | Add |
| 36 | AUTL | Autolus Therapeutics PLC | -0.8% | -84.76% | Trim |
| 37 | IMVT | Immunovant Inc | -0.9% | +2.41% | Add |
| 38 | BBIO | Bridgebio Pharma Inc | -1.4% | +33.33% | Trim |
| 39 | PTGX | Protagonist Therapeutics Inc | -1.5% | -47.14% | Trim |
| 40 | DVAX | Dynavax Technologies CORP | -3.1% | -11.61% | Trim |
| 41 | ITCIEUR | Intra-cellular Therapies Inc | — | EXIT | Sold out |
| 42 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 43 | SRPT | Sarepta Therapeutics Inc | — | EXIT | Sold out |
| 44 | EXK | Exact Sciences CORP | — | NEW | New buy |
| 45 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 46 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 47 | DNTH | Dianthus Therapeutics Inc | — | EXIT | Sold out |
| 48 | AMGN | Amgen Inc | — | EXIT | Sold out |
| 49 | EWTX | Edgewise Therapeutics Inc | — | EXIT | Sold out |
| 50 | ✓ | — | EXIT | Sold out |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 56 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including GH, IONS, CYTK) accounted for 16.2% of total reported equity market value during Q3 2025.
Top New Position Initiated
AXSM
市值: $109.3M
Top Position Liquidated / Trimmed
ITCIEUR
前期市值: $263.8M
During Q3 2025, Deep Track Capital, LP's top holdings by market value included GH (7.2%)、IONS (7.0%)、CYTK (6.6%). The largest single position, GH, represented 7.2% of total portfolio value.
In Q3 2025, Deep Track Capital, LP made 79 total portfolio adjustments, initiating 16 new buys, adding to 18 positions, trimming 16 holdings, and fully liquidating 29 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.